196 related articles for article (PubMed ID: 17580145)
1. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
Legendre C; Cohen D; Zeier M; Rostaing L; Budde K
Transplant Proc; 2007 Jun; 39(5):1386-91. PubMed ID: 17580145
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study.
Vogt B; Antoniadis A; Klinger M; Vitko S
Transplant Proc; 2006 Jun; 38(5):1301-6. PubMed ID: 16797288
[TBL] [Abstract][Full Text] [Related]
3. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies.
Pietruck F; Abbud-Filho M; Vathsala A; Massari PU; Po-Huang L; Nashan B
Transplant Proc; 2007; 39(1):103-8. PubMed ID: 17275484
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
8. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
10. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
[TBL] [Abstract][Full Text] [Related]
11. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
12. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study.
Nashan B; Ivens K; Suwelack B; Arns W; Abbud Filho M; ;
Transplant Proc; 2004 Mar; 36(2 Suppl):521S-523S. PubMed ID: 15041400
[TBL] [Abstract][Full Text] [Related]
14. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
15. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
Cibrik D; Meier-Kriesche HU; Bresnahan B; Wu YM; Klintmalm G; Kew CE; Kuo PC; Whelchel J; Cohen D; Baliga P; Akalin E; Benedetti E; Wright F; Lieberman B; Ulbricht B; Jensik S;
Clin Transplant; 2007; 21(2):192-201. PubMed ID: 17425744
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
[TBL] [Abstract][Full Text] [Related]
17. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function.
Schiavelli R; Gaite L; Agost Carreno C; Baran M; Novoa P; Massari P; Otero AB; Piulats E
Transplant Proc; 2006 Apr; 38(3):905-8. PubMed ID: 16647505
[TBL] [Abstract][Full Text] [Related]
18. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients.
Rostaing L; Mourad G; Kamar N; Garrigue V; Karras A; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Berthoux F; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Legendre C;
Transplant Proc; 2006 Nov; 38(9):2860-3. PubMed ID: 17112849
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]